Loading...
UK Trademark — IPO
TULIPIA Trial Using BIM23A760 dose Levels In Patients In Acromegaly
Application UK00909310889 · DO-NOT-DISPLAY
Quick Facts
| Application Number | UK00909310889 |
| Status | DO-NOT-DISPLAY |
| Owner | Ipsen Pharma S.A.S |
| Filed | 2010-07-26 |
| Registered | 2011-02-10 |
| Renewal Due | 2020-07-26 |
| Type | Individual |
| Feature | Word |
| Attorney | See claim section below |
Is this trademark active?
TULIPIA Trial Using BIM23A760 dose Levels In Patients In Acromegaly has a current status of DO-NOT-DISPLAY.
Goods & Services
The specification below is taken directly from the filed record at the UK IPO for each Nice class this trademark is registered in.
Class 42 — Scientific & IT Services
Conducting of programmes for medical, pharmaceutical and scientific research, conducting of analyses and clinical research, scientifi, medical and pharmaceutical research.
Timeline
- Filed: 2010-07-26
- Registered: 2011-02-10
- Renewal due: 2020-07-26
About This Trademark
'TULIPIA Trial Using BIM23A760 dose Levels In Patients In Acromegaly' is a do-not-display trademark on the UK IPO register, owned by Ipsen Pharma S.A.S. The application (UK00909310889) was filed on 26 July 2010 and registered on 10 February 2011. The registration is set to expire on 26 July 2020.
This mark is recorded under Class 42 (scientific, IT & design services).
The trademark is represented by Hélène Bernard-Boyle IPSEN PHARMA S.A.S.
Frequently Asked Questions
Who owns UK trademark UK00909310889 ('TULIPIA Trial Using BIM23A760 dose Levels In Patients In Acromegaly')?
UK trademark UK00909310889 for the mark 'TULIPIA Trial Using BIM23A760 dose Levels In Patients In Acromegaly' in Class 42 is recorded on the UK IPO register as owned by Ipsen Pharma S.A.S. This covers one specific UK trademark record only — the same brand name may be owned by different parties in other classes, other countries, or as separate registrations.
Is UK trademark UK00909310889 currently a registered trademark?
No — the UK IPO records the status of UK trademark UK00909310889 for the mark 'TULIPIA Trial Using BIM23A760 dose Levels In Patients In Acromegaly' as do-not-display.
Which goods or services does UK trademark UK00909310889 cover?
UK trademark UK00909310889 for the mark 'TULIPIA Trial Using BIM23A760 dose Levels In Patients In Acromegaly' is registered in Class 42 (scientific, IT & design services). The filed specification reads: Class 42: Conducting of programmes for medical, pharmaceutical and scientific research, conducting of analyses and clinical research, scientifi, medical and pharmaceutical research.
When was UK trademark UK00909310889 filed?
UK trademark UK00909310889 for the mark 'TULIPIA Trial Using BIM23A760 dose Levels In Patients In Acromegaly' was filed at the UK IPO on 26 July 2010 and registered on 10 February 2011.
When does UK trademark UK00909310889 need to be renewed?
UK trademark UK00909310889 for the mark 'TULIPIA Trial Using BIM23A760 dose Levels In Patients In Acromegaly' is currently recorded as valid until 26 July 2020, at which point it will need to be renewed with the UK IPO to remain in force.
Who is the attorney of record for UK trademark UK00909310889?
Hélène Bernard-Boyle IPSEN PHARMA S.A.S is listed as the attorney / representative of record for UK trademark UK00909310889 for the mark 'TULIPIA Trial Using BIM23A760 dose Levels In Patients In Acromegaly' on the UK IPO register.
Attorney of Record
This trademark has an attorney of record listed on the UK register. The firm has not yet claimed its listing on Trademark Dashboard.
Cross-Register Filings
Trademarks matching "TULIPIA Trial Using BIM23A760 dose Levels In Patients In Acromegaly" have been found on the following foreign registers. Exact matches appear first; where the name also appears inside longer filings, those are listed below as similar marks. A “Same applicant” badge appears next to a mark when the applicant name aligns with the source filing.
US — United States (USPTO)
| Mark | Ref | Status | Filed |
|---|---|---|---|
| TULIPIA TRIAL USING BIM23A760 DOSE LEVELS IN PATIENTS IN ACROMEGALYSame applicant | 79089155 | 402 | 2010-10-14 |
Data Source
United Kingdom (Intellectual Property Office)
UK trademark data is supplied by the Intellectual Property Office under the Open Government Licence v3.0.
United States (USPTO)
US trademark data is supplied by the United States Patent and Trademark Office. Works of the US federal government are in the public domain under 17 U.S.C. §105.
The “About This Trademark” summary and FAQ above are AI-generated from the register data shown on this page. They are factual summaries only — always verify details against the official register before making legal decisions.